Z_max test for delayed effect in immuno-oncology clinical trials

References

• Chen, T. T. 2013. Statistical issues and challenges in immuno-oncology. Journal for Immunotherapy of Cancer 1 (1):18. doi:10.1186/2051-1426-1-18.
   PubMedGoogle Scholar
• Cohen, E. E., K. J. Harrington, C. Le Tourneau, J. Dinis, L. Licitra, M. J. Ahn, A. Soria, J. P. Machiels, N. Mach, R. Mehra, et al. 2017. LBA45_PRPembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. Annals of Oncology 28 (suppl_5).
   Google Scholar
• Cox, D. R. 1972. Regression models and life-tables. Journal of the Royal Statistical Society. Series B (Methodological) 34 (2):187–220. doi:10.1111/j.2517-6161.1972.tb00899.x.
   Web of Science ®Google Scholar
• Ferris, R. L., G. Blumenschein Jr, J. Fayette, J. Guigay, A. D. Colevas, L. Licitra, K. Harrington, S. Kasper, E. E. Vokes, C. Even, et al. 2016. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New England Journal of Medicine 375 (19):1856–1867. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Fine, G. D. 2007. Consequences of delayed treatment effects on analysis of time-to-event endpoints. Drug Information Journal 41 (4):535–539. doi:10.1177/009286150704100412.
   Google Scholar
• Fleming, T. R., and D. P. Harrington. 1991. Counting processes and survival analysis. New York: John Wiley & Sons.
   Google Scholar
• Gehan, E. A. 1965. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203–224. doi:10.1093/biomet/52.1-2.203.
   PubMed Web of Science ®Google Scholar
• Gill, R. D. 1980. Censoring and stochastic integrals. Statistica Neerlandica 34 (2):124. doi:10.1111/stan.1980.34.issue-2.
   Google Scholar
• Guyot, P., A. E. Ades, M. J. Ouwens, and N. J. Welton. 2012. Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology 12 (1):9. doi:10.1186/1471-2288-12-9.
   PubMed Web of Science ®Google Scholar
• Harrington, D. P., and T. R. Fleming. 1982. A class of rank test procedures for censored survival data. Biometrika 69 (3):553–566. doi:10.1093/biomet/69.3.553.
   Web of Science ®Google Scholar
• Hasegawa, T. 2014. Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies. Pharmaceutical Statistics 13 (2):128–135. doi:10.1002/pst.v13.2.
   PubMed Web of Science ®Google Scholar
• Herbst, R. S., P. Baas, D. W. Kim, E. Felip, J. L. Pérez-Gracia, J. Y. Han, J. Molina, J. H. Kim, C. D. Arvis, M. J. Ahn, et al. 2016. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. The Lancet 387 (10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Hoos, A. 2012. Evolution of end points for cancer immunotherapy trials. Annals of Oncology 23 (8):47–52. doi:10.1093/annonc/mds263.
   Google Scholar
• Hoos, A., A. M. Eggermont, S. Janetzki, F. S. Hodi, R. Ibrahim, A. Anderson, R. Humphrey, B. Blumenstein, L. Old, and J. Wolchok. 2010. Improved endpoints for cancer immunotherapy trials. Journal of the National Cancer Institute 102 (18):1388–1397. doi:10.1093/jnci/djq310.
   PubMed Web of Science ®Google Scholar
• Kalbfleisch, J. D. 1978. Likelihood methods and nonparametric tests. Journal of the American Statistical Association 73 (361):167–170. doi:10.1080/01621459.1978.10480021.
   Web of Science ®Google Scholar
• Kalbfleisch, J. D., and R. L. Prentice. 1981. Estimation of the average hazard ratio. Biometrika 68 (1):105–112. doi:10.1093/biomet/68.1.105.
   Web of Science ®Google Scholar
• Karrison, T. G. 2016. Versatile tests for comparing survival curves based on weighted log-rank statistics. Stata Journal 16 (3):678–690. doi:10.1177/1536867X1601600308.
   Web of Science ®Google Scholar
• Kaufman, H., L. H. Schwartz, W. N. William, M. Sznol, M. Del Aguila, C. Whittington, K. Fahrbach, Y. Xu, E. Masson, S. Dempster, et al. 2017. Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies. doi:10.1200/JCO.2017.35.15_suppl.e14557.
   Google Scholar
• Lachin, J. M., and M. A. Foulkes. 1986. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42 (3):507–519. doi:10.2307/2531201.
   PubMed Web of Science ®Google Scholar
• Lakatos, E. 1988. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 44:229–241. doi:10.2307/2531910.
   PubMed Web of Science ®Google Scholar
• Lee, J. W. 1996. Some versatile tests based on the simultaneous use of weighted log-rank statistics. Biometrics 721–725. doi:10.2307/2532911.
   Web of Science ®Google Scholar
• Lee, S. H. 2007. On the versatility of the combination of the weighted log-rank statistics. Computational Statistics & Data Analysis 51 (12):6557–6564. doi:10.1016/j.csda.2007.03.006.
   Web of Science ®Google Scholar
• Lin, R. S., and L. F. León. 2017. Estimation of treatment effects in weighted log-rank tests. Contemporary Clinical Trials Communications 8:147–155. doi:10.1016/j.conctc.2017.09.004.
   PubMed Web of Science ®Google Scholar
• Mantel, N. 1966. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 50 (3):163–170.
   PubMedGoogle Scholar
• Motzer, R. J., B. Escudier, D. F. McDermott, S. George, H. J. Hammers, S. Srinivas, S. S. Tykodi, J. A. Sosman, G. Procopio, E. R. Plimack, et al. 2015. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine 373 (19):1803–1813. doi:10.1056/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Peto, R. 1972. Rank tests of maximal power against Lehmann-type alternatives. Biometrika 59 (2):472–475. doi:10.1093/biomet/59.2.472.
   Web of Science ®Google Scholar
• Peto, R., and J. Peto. 1972. Asymptotically efficient rank invariant test procedures (with discussion). Journal of the Royal Statistical Society, Series A (General) 135 (2):185–207. doi:10.2307/2344317.
   Web of Science ®Google Scholar
• Rao, C. R. 2001. Linear statistical inference and its applications. New York: John Wiley & Sons.
   Google Scholar
• Schemper, M., S. Wakounig, and G. Heinze. 2009. The estimation of average hazard ratios by weighted Cox regression. Statistics in Medicine 28 (19):2473–2489. doi:10.1002/sim.v28:19.
   PubMed Web of Science ®Google Scholar
• Schoenfeld, D. 1981. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 68:316–318. doi:10.1093/biomet/68.1.316.
   Web of Science ®Google Scholar
• Self, S., R. Prentice, D. Iverson, M. Henderson, D. Thompson, D. Byar, W. Insull, S. L. Gorbach, C. Clifford, S. Goldman, et al. 1988. Statistical design of the women’s health trial. Controlled Clinical Trials 9 (2):119–136. doi:10.1016/0197-2456(88)90033-5.
   PubMedGoogle Scholar
• Serfling, R. J. 2009. Approximation theorems of mathematical statistics (Vol. 162). New York: John Wiley & Sons.
   Google Scholar
• Sit, T., M. Liu, M. Shnaidman, and Z. Ying. 2016. Design and analysis of clinical trials in the presence of delayed treatment effect. Statistics in Medicine 35 (11):1774–1779. doi:10.1002/sim.v35.11.
   PubMed Web of Science ®Google Scholar
• Tarone, R. E., and J. Ware. 1977. On distribution-free tests for equality of survival distributions. Biometrika 64 (1):156–160. doi:10.1093/biomet/64.1.156.
   Web of Science ®Google Scholar
• Xu, Z., B. G. Zhen, Y. Park, and B. Zhu. 2017. Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in Medicine 36:592–605. doi:10.1002/sim.7157.
   PubMed Web of Science ®Google Scholar
• Yang, M., Z. Hua, and S. Vardhanabhuti. 2019. Sample size determination under non-proportional hazards. In: Pharmaceutical statistics, ed. R. Liu and Y. Tsong, 157–165. MBSW 2016. Springer Proceedings in Mathematics & Statistics, vol. 218. Cham: Springer. doi:10.1007/978-3-319-67386-8_12.
   Google Scholar
• Yang, S., L. Hsu, and L. Zhao. 2005. Combining asymptotically normal tests: Case studies in comparison of two groups. Journal of Statistical Planning and Inference 133 (1):139–158. doi:10.1016/j.jspi.2004.03.007.
   Web of Science ®Google Scholar
• Yang, S., and R. Prentice. 2010. Improved logrank-type tests for survival data using adaptive weights. Biometrics 66 (1):30–38. doi:10.1111/j.1541-0420.2009.01243.x.
   PubMed Web of Science ®Google Scholar
• Zhang, D., and H. Quan. 2009. Power and sample size calculation for log-rank test with a time lag in treatment effect. Statistics in Medicine 28 (5):864–879. doi:10.1002/sim.v28:5.
   PubMed Web of Science ®Google Scholar
• Zucker, D. M., and E. Lakatos. 1990. Weighted log rank type statistics for comparing survival curves when there is a time lag in the effectiveness of treatment. Biometrika 77:853–864. doi:10.1093/biomet/77.4.853.
   Web of Science ®Google Scholar